Back to top
more

WAVE Life Sciences (WVE)

(Delayed Data from NSDQ)

$5.90 USD

5.90
438,902

+0.06 (1.03%)

Updated May 15, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (92 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Wave Life Sciences Enters Oversold Territory

by Zacks Equity Research

Wave Life Sciences Ltd. (WVE) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Options Traders Expect Huge Moves in Wave Life Sciences (WVE) Stock

by Zacks Equity Research

Investors need to pay close attention to Wave Life Sciences (WVE) stock based on the movements in the options market lately.

Implied Volatility Surging for Wave Life Sciences (WVE) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Wave Life Sciences (WVE) stock based on the movements in the options market lately.

Wave Life Sciences (WVE) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Wave Life Sciences (WVE) delivered earnings and revenue surprises of -6.47% and -53.54%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Wave Life Sciences (WVE) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

by Zacks Equity Research

Wave Life Sciences (WVE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Wave Life Sciences (WVE) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Wave Life Sciences (WVE) delivered earnings and revenue surprises of -16.19% and -51.61%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Sarepta Up as Pfizer's DMD Gene Therapy Faces Safety Issues

by Zacks Equity Research

Sarepta's (SRPT) shares surge after safety issues are observed in Pfizer's early-stage clinical study related to its gene therapy for DMD.

Wave Life Sciences (WVE) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Wave Life Sciences (WVE) delivered earnings and revenue surprises of -14.29% and -68.69%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Wave Life Sciences (WVE) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

by Zacks Equity Research

Wave Life Sciences (WVE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Wave Life Sciences Plunges After DMD Study Data Readout

by Zacks Equity Research

Wave Life Sciences (WVE) announces final safety data from a phase I DMD study evaluating suvodirsen and provides design update for phase II/III stage development of the candidate.

Wave Life Sciences (WVE) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Wave Life Sciences (WVE) delivered earnings and revenue surprises of -2.40% and -16.18%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Wave Life Sciences (WVE) Q3 Earnings Expected to Decline

by Zacks Equity Research

Wave Life Sciences (WVE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Wave Life Sciences (WVE) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Wave Life Sciences (WVE) delivered earnings and revenue surprises of -11.82% and -33.84%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?